Group 1 - The company held its 30th meeting of the 5th board of directors, which was conducted both in-person and via electronic communication [1] - The board approved the establishment of Chengdu Xuecao Biotechnology Co., Ltd. in collaboration with Qinghai Chenxin Biotechnology Co., Ltd. and Mr. Zheng Weidong to enhance production capacity and optimize product structure [1][2] - Chengdu Xuecao will focus on the research, cultivation, and sales of Cordyceps sinensis, with a registered capital of 20 million yuan [2] Group 2 - Chengdu Xuelong will contribute 10.2 million yuan, accounting for 51% of the registered capital, while Chenxin Biotechnology will contribute 7 million yuan (35%) and Mr. Zheng Weidong will contribute 2.8 million yuan (14%) [2] - The investment proposal received unanimous approval from the board members, with 6 votes in favor and no opposition [2] - The company plans to apply for a credit facility of up to 1 billion yuan from China Construction Bank, with the decision also receiving unanimous support from the board [2]

证券代码：300511 证券简称：雪榕生物 公告编号：2025-073 债券代码：123056 债券简称：雪榕转债 本次会议的召开符合《公司法》《公司章程》及有关法律、法规的规定。 二、监事会会议审议情况 经审议，监事会认为：本次全资子公司对外投资符合公司战略发展需要，本 次关联交易定价公允，公平，审议程序符合有关法律、法规和《公司章程》的规 定，不存在损害公司及全体股东利益的情形。因此，监事会同意本次关联交易事 项。 具体内容详见公司公布在中国证监会指定创业板信息披露网站巨潮资讯网 的《关于全资子公司对外投资设立控股子公司暨关联交易的公告》（公告编号： 本议案以 3 票同意，0 票反对，0 票弃权获得通过。 三、备查文件 特此公告。 上海雪榕生物科技股份有限公司 第五届监事会第十七次会议决议公告 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 上海雪榕生物科技股份有限公司（以下简称"公司"）第五届监事会第十七次 会议通知于 2025 年 7 月 29 日以电话等方式通知全体监事，并于 2025 年 8 月 4 日以现场投票表决的方式在 ...

证券代码：300511 证券简称：雪榕生物 公告编号：2025-074 债券代码：123056 债券简称：雪榕转债 上海雪榕生物科技股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 与度，本次股东大会对审议影响中小投资者利益的重大事项时进行单独计票，中 小投资者是指除上市公司董事、监事、高级管理人员以及单独或者合计持有公司 一、会议召开情况 （1）现场会议召开时间：2025 年 8 月 4 日 14:30； （2）网络投票时间：2025 年 8 月 4 日，其中： ①通过深圳证券交易所（以下简称"深交所"）交易系统进行网络投票的时间 为：2025 年 8 月 4 日 9:15-9:25，9:30-11:30 和下午 13:00-15:00； ①通过深交所互联网系统投票的具体时间为：2025 年 8 月 4 日 9:15 至 15:00 的任意时间。 司法》《证券法》等相关法律法规及《公司章程》的规定。 二、会议出席情况 通过现场和网络投票出席会议的股东共计 273 人(含授权委托 1 人)，代表股 份总数为 131,860,107 股， ...

Group 1 - The company held its second extraordinary general meeting of shareholders in 2025 on August 4, 2025, at a specified location in Shanghai, combining both in-person and online participation [3][4] - The meeting was convened following a proposal from the company's board of directors on July 17, 2025, and the notice was published on July 18, 2025, in accordance with legal requirements [2][3] - A total of 3 shareholders attended the meeting, representing 126,370,700 shares, which accounts for 21.1448% of the company's total shares [4] Group 2 - The voting process included both on-site and online voting, with specific time slots allocated for online participation on the same day [3][5] - The meeting's agenda was approved through a voting process that adhered to the company's articles of association, ensuring the protection of minority investors by counting votes separately for them [5] - The legal opinion concluded that all procedures for convening and conducting the meeting, as well as the qualifications of attendees and the voting process, were in compliance with relevant laws and regulations [5]

Core Viewpoint - The company Snow Rong Bio announced the establishment of a new subsidiary, Chengdu Snow Grass Biotechnology Co., Ltd., in collaboration with Qinghai Chenxin Biotechnology Co., Ltd. and Mr. Zheng Weidong, focusing on the research, cultivation, and sales of Cordyceps sinensis, aligning with its multi-product strategy and aiming to enhance production capacity and reduce costs in its edible fungi business [1] Group 1 - Chengdu Snow Grass will have a registered capital of 20 million yuan, with Snow Rong Bio contributing 10.2 million yuan, accounting for 51% of the investment [1] - Qinghai Chenxin will contribute 7 million yuan in intangible assets, representing 35% of the investment [1] - Mr. Zheng Weidong will invest 2.8 million yuan, holding a 14% stake in the new company [1] Group 2 - The establishment of Chengdu Snow Grass is part of the company's strategy to diversify its product offerings and is expected to improve the utilization rate of existing production capacity [1] - This investment represents the company's attempt to venture into high-end products within the industry [1]

（文章来源：证券日报） 证券日报网讯 8月4日晚间，雪榕生物发布公告称，公司2025年第二次临时股东大会于2025年8月4日召 开，审议通过了《关于拟为子公司提供担保的议案》。 ...

证券日报网讯 8月4日晚间，雪榕生物发布公告称，公司第五届董事会第三十次会议审议通过了《关于 全资子公司对外投资设立控股子公司暨关联交易的议案》等多项议案。 （文章来源：证券日报） ...

证券日报网讯 8月4日晚间，雪榕生物发布公告称，公司第五届监事会第十七次会议审议通过了《关于 全资子公司对外投资设立控股子公司暨关联交易的议案》。 （文章来源：证券日报） ...

Core Viewpoint - Xuerong Biotechnology (300511.SZ) is establishing a new company, Chengdu Xuesao Biotechnology Co., Ltd., to enhance production capacity utilization and optimize product structure through a multi-variety layout strategy [1] Group 1: Company Investment and Structure - Chengdu Xuesao will be jointly funded by Chengdu Xuerong, Qinghai Chenxin Biotechnology Co., Ltd., and Mr. Zheng Weidong, with a registered capital of 20 million yuan [1] - Chengdu Xuerong will contribute 10.2 million yuan, holding a 51% stake, while Chenxin Biotechnology will contribute 7 million yuan for a 35% stake, and Mr. Zheng will invest 2.8 million yuan for a 14% stake [1] - The primary focus of Chengdu Xuesao will be on the research, cultivation, and sales of Cordyceps sinensis [1]

雪榕生物（SZ 300511，收盘价：6.41元）8月4日晚间发布公告称，公司第五届第三十次董事会会议于 2025年8月4日在上海雪榕生物科技股份有限公司会议室召开。会议审议了《关于公司向建设银行申请综 合授信的议案》等文件。 2024年1至12月份，雪榕生物的营业收入构成为：食用菌行业占比98.62%，其他业务占比1.38%。 （文章来源：每日经济新闻） ...